Robert Kassees

Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

Jie Lin, Deepak Sampath, Michelle Nannini et al. · Clinical Cancer Research · 2013 · 295 citations

Medicine, Oncology, Pharmacology +16

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Jeffrey J. Wallin, Kyle A. Edgar, Jane Guan et al. · Molecular Cancer Therapeutics · 2011 · 228 citations

Medicine, Oncology, Pharmacology +16

Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models

Nguyen Tan, Mehnaz Malek, Jiping Zha et al. · Clinical Cancer Research · 2011 · 102 citations · Full text

Medicine, Oncology, Pharmacology +17

Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer

Jeffrey J. Wallin, Jane Guan, Wei Wei Prior et al. · Science Translational Medicine · 2010 · 63 citations

Medicine, Oncology, Pharmacology +17

Preclinical Disposition of GDC-0973 and Prospective and Retrospective Analysis of Human Dose and Efficacy Predictions

Edna F. Choo, Marcia Belvin, Jason Boggs et al. · Drug Metabolism and Disposition · 2012 · 35 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13